EDEN PRAIRIE, Minn., Nov. 15, 2018 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS), today announces the launch of its new educational webinar featuring Daniel Beckles, M.D., Ph.D., director of Minimally Invasive Cardiothoracic Surgery at UHS Heart and Vascular Institute, Vestal, N.Y. The webinar can be accessed on the company’s website, www.chf-solutions.com.
The 17-minute, pre-recorded webinar is designed to provide medical professionals with an overview of the common clinical issues associated with fluid overload in the cardiac surgery space and how the company’s Aquadex FlexFlow system may provide a clinical solution to removing excess fluid for post-cardiac surgery patients, who have failed diuretic therapy.
“Fluid overload poses a tremendous potential risk following cardiac surgery, and improper fluid management can result in complications, readmissions, and increased mortality,” said Dr. Beckles. “My hope in providing this overview is to educate professionals on the potential risks and to demystify cardiorenal syndrome. With solutions such as Aquadex FlexFlow therapy, surgeons can treat fluid overload post-cardiac surgery and, I believe, can improve overall quality and patient outcomes.”
Topics covered include:
- Trends in adult cardiovascular surgery
- Complications resulting from cardiovascular surgery, including fluid overload
- The role of ultrafiltration in post-op cardiovascular patients
- Aquadex FlexFlow and first-hand experience using the device following cardiac surgery
“Providing this webinar for medical professionals supports our ongoing strategy to highlight the multiple uses of our Aquadex FlexFlow system. We recently announced expanded commercialization of Aquadex FlexFlow therapy into the post-cardiovascular surgery market, and Dr. Beckles’s experience supports the value of that approach,” commented John Erb, chairman and CEO of CHF-Solutions. “We will continue to explore the best ways to optimize patient care through fluid management and look forward to the opportunity to inform medical professionals and investors on our approach and execution.”
About CHF Solutions
CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company’s mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the potential of our expansion into the post-cardiovascular surgery market to be commercially successful and result in growth of the market for the Aquadex Flex Flow system and the ability for the Aquadex FlexFlow system to improve patient outcomes. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with, and benefits from, acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions, Inc. does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com
